Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Julie Rivers"'
Autor:
Karen, MacKinnon, Lenora, Marcellus, Julie, Rivers, Carol, Gordon, Maureen, Ryan, Diane, Butcher
Publikováno v:
JBI Database of Systematic Reviews and Implementation Reports. 15:2666-2706
Although maternal-child care is a pillar of primary health care, there is a global shortage of maternal-child health care providers. Nurse educators experience difficulties providing undergraduate students with maternal-child learning experiences for
Autor:
Hannah Brakke, Olivia Finney, Kasey J. Leger, Juliane Gust, Todd M. Cooper, Rebecca Gardner, Daniel H. Li, Julie Rivers, Corinne Summers, Julie R. Park, Francesco Ceppi, Michael C. Jensen, Agne Taraseviciute, Colleen Annesley, Katherine Tarlock
Publikováno v:
Blood. 134(24)
Immunotherapy with the adoptive transfer of T cells redirected with CD19-specific chimeric antigen receptors (CARs) for B-lineage acute lymphoblastic leukemia (ALL) can salvage >80% of patients having relapsed/refractory disease. The therapeutic inde
Autor:
Christopher Brown, Adam Brand, Qian Vicky Wu, Karen Spratt, Michael C. Jensen, Stephanie Mgebroff, Adam J. Lamble, Adam Johnson, Rebecca Gardner, Julie R. Park, Corinne Summers, Catherine Lindgren, Julie Rivers, Ashley Wilson, Colleen Annesley
Publikováno v:
Blood. 134:223-223
Background: While immunotherapy withCD19 specific CAR T cells for relapsed/refractory (R/R) B-ALL achieves MRD negative remission in nearly all patients, relapse occurs in approximately half of patients and is frequently associated with early loss of
Autor:
Adam J. Lamble, Adam Brand, Alan S. Wayne, Ashley Wilson, Christopher Brown, Julie Rivers, Qian Vicky Wu, Michael C. Jensen, Michael A. Pulsipher, Colleen Annesley, Corinne Summers, Stephanie Mgebroff, Rebecca Gardner, Julie R. Park, Catherine Lindgren
Publikováno v:
Blood. 134:3869-3869
Background: The youngest patients referred for CAR T cell therapy are those with relapsed or refractory (R/R) KMT2A-rearranged infant B-ALL. Infants with relapsed ALL following Interfant-99 therapy have a dismal reported 3-yr OS of 20.9%, indicating
Autor:
Catherine Lindgren, Navin Pinto, Francesco Ceppi, Julie Rivers, Naomi Linn, Meghan Delaney, Colleen Annesley, Stephanie Mgebroff, Rebecca Gardner, Julie R. Park
Publikováno v:
Transfusion. 58(6)
Background The first step in the production of chimeric antigen receptor T cells is the collection of autologous T cells using apheresis technology. The procedure is technically challenging, because patients often have low leukocyte counts and are he
Autor:
Michelle Jarvis, Julie Rivers
Publikováno v:
Nurse Educator. 39:179-183
Campus Clinical is a simulation-based curriculum designed to meet the challenge of decreasing clinical spaces in maternal-child units. The curriculum framework is situated in a constructivist, experiential learning context, integrating Chickering and
Autor:
Alan S. Wayne, Olivia Finney, Corinne Summers, Julie Rivers, Michael C. Jensen, Colleen Annesley, Rebecca Gardner, Julie R. Park, Michael A. Pulsipher
Publikováno v:
Blood. 132:2957-2957
Background:Pediatric patients with relapsed or refractory CD19+non-Hodgkin lymphoma (NHL) have poor outcomes despite use of chemotherapy and hematopoietic stem cell transplant (HSCT). Clinical trials of CD19 CAR T-cells have demonstrated efficacy in
Autor:
Adam Johnson, Karen Spratt, Olivia Finney, Christopher Brown, Julie Rivers, Colleen Annesley, Corinne Summers, Stephanie Mgebroff, Catherine Lindgren, Rebecca Gardner, Julie R. Park, Adam J. Lamble, Michael C. Jensen
Publikováno v:
Blood. 132:4021-4021
Background: Immunotherapy with CD19 specific chimeric antigen receptor (CAR) T cells for relapsed/refractory acute lymphoblastic leukemia (ALL) demonstrated a minimal residual disease (MRD) negative remission rate of 93% on the phase 1 portion of Ped
Autor:
Kaelin Crews, Adam Johnson, Stephanie Mgebroff, Adam J. Lamble, Karen Spratt, Corinne Summers, Rebecca Gardner, Catherine Lindgren, Julie R. Park, Christopher Brown, Olivia Finney, Michael C. Jensen, Colleen Annesley, Josh Gustafson, Lauren Huang, Julie Rivers
Publikováno v:
Blood. 132:278-278
Introduction: Advances in chimeric antigen receptor (CAR) T cell therapy have yielded complete remission (CR) rates in relapsed/refractory B-ALL (rrB-ALL) of 70-95%. However, disease recurrence after CD19 or CD22 CAR therapy is greater than 50% at 1
Autor:
Carol Gordon, Maureen M. Ryan, Lenora Marcellus, Karen MacKinnon, Diane Butcher, Julie Rivers
Publikováno v:
JBI database of systematic reviews and implementation reports. 13(1)
The overall aim of this systematic review is to identify the appropriateness and meaningfulness of maternal-child simulation-based learning for undergraduate or pre-registration nursing students in educational settings to inform curriculum decision-m